Answers are grounded in this paper and cite their sources.
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. CCAs tend to metastasize with early lymph node involvement lending to poor surgical outcomes and need for systemic therapy. Given the paucity of successful therapies in these cancers, it is important to understand the molecular drivers and to develop therapeutic strategies using targeted therapies either alone or in combination. The molecular landscape offers several new potentially targetable drivers.
No takes yet. Share an insight, caveat, or question.
Kalyan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: